449 related articles for article (PubMed ID: 18715233)
1. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
Jiang CC; Lai F; Tay KH; Croft A; Rizos H; Becker TM; Yang F; Liu H; Thorne RF; Hersey P; Zhang XD
Cell Death Dis; 2010 Sep; 1(9):e69. PubMed ID: 21364673
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
Sheridan C; Brumatti G; Martin SJ
J Biol Chem; 2008 Aug; 283(32):22128-35. PubMed ID: 18508762
[TBL] [Abstract][Full Text] [Related]
4. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ
Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Pei XY; Dai Y; Tenorio S; Lu J; Harada H; Dent P; Grant S
Blood; 2007 Sep; 110(6):2092-101. PubMed ID: 17540843
[TBL] [Abstract][Full Text] [Related]
6. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
7. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
Sale MJ; Cook SJ
Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
[TBL] [Abstract][Full Text] [Related]
8. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Shao Y; Aplin AE
Cell Death Differ; 2012 Dec; 19(12):2029-39. PubMed ID: 22858545
[TBL] [Abstract][Full Text] [Related]
9. Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells.
Goldstein NB; Johannes WU; Gadeliya AV; Green MR; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Feb; 129(2):432-7. PubMed ID: 18668139
[TBL] [Abstract][Full Text] [Related]
10. Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Boisvert-Adamo K; Aplin AE
Oncogene; 2008 May; 27(23):3301-12. PubMed ID: 18246127
[TBL] [Abstract][Full Text] [Related]
11. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
12. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.
Croft A; Tay KH; Boyd SC; Guo ST; Jiang CC; Lai F; Tseng HY; Jin L; Rizos H; Hersey P; Zhang XD
J Invest Dermatol; 2014 Feb; 134(2):488-497. PubMed ID: 23921951
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibition overcomes resistance to TRAIL-induced apoptosis in melanoma cells.
Berger A; Quast SA; Plötz M; Kuhn NF; Trefzer U; Eberle J
J Invest Dermatol; 2014 Feb; 134(2):430-440. PubMed ID: 23955071
[TBL] [Abstract][Full Text] [Related]
15. Skin mild hypoxia enhances killing of UVB-damaged keratinocytes through reactive oxygen species-mediated apoptosis requiring Noxa and Bim.
Nys K; Maes H; Andrei G; Snoeck R; Garmyn M; Agostinis P
Free Radic Biol Med; 2012 Mar; 52(6):1111-20. PubMed ID: 22245094
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
17. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
[TBL] [Abstract][Full Text] [Related]
19. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
Deuker MM; Marsh Durban V; Phillips WA; McMahon M
Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.
Gao Z; Shang Q; Liu Z; Deng C; Guo C
Oncotarget; 2015 Nov; 6(34):36338-53. PubMed ID: 26462148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
